spacer
home > ebr > summer 2004 > why is scientific due diligence essential in drug development?
PUBLICATIONS
European Biopharmaceutical Review

Why is Scientific Due Diligence Essential in Drug Development?

Due diligence is the process of acquiring objective and reliable information, prior to a specific event or decision. By common agreement, due diligence means 'making sure you get what you think you are paying for'. It is not measured by any absolute standard but depends on the relative facts of the special case. In order to effectively perform due diligence, it is essential to have an understanding of what really matters with respect to the decision at hand. This requires expertise in various areas such as competitive pharma/biotech landscapes, the customer marketplace, operations, business development, strategy, business analysis and technical or scientific expertise. Without this kind of experience, it is difficult to truly know what may be significant risks, specific to any given situation. Only this expertise guarantees that the significant risks are identified and quantified, and that the right questions are addressed to the right people. Working according to a standard list will not suffice.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Konrad Burk, Founder of ClinDescience GmbH, Dr William McCulloch, CMO of Gloucester Pharmaceuticals, Dr Alexander von Nieciecki, CEO of BioProof, and Dr Wolfgang Meyer, Senior Director of European Drug Regulatory Affairs and Dr Benno Rattel, Senior Director of Drug Development at GPC Biotech AG

Dr Konrad Burk is Professor of Urology and a member of the faculty at Frankfurt University, Medical School in Germany. He has been active in the field of oncology for more than 25 years. After 15 years of clinical work in urology and oncology, he entered industry in 1987. As Head of R&D, he has been responsible for clinical development in three companies and has been involved in the evaluation of numerous compounds for in-licensing. In 2001, Dr Burk founded ClinDescience GmbH, where he offers his expertise in drug and clinical development of oncological therapeutics to pharmaceutical and biotech companies, as well as due diligence services to venture capital firms.


Dr William McCulloch earned his MB ChB from the University of Glasgow in Scotland. He is a Member of the Royal College of Physicians (UK) and a Fellow of the Royal College of Physicians (Glasgow). He practised Medicine for seven years in the UK. His areas of responsibility have included non clinical and clinical development, regulatory and medical affairs, licensing and sales force training, with a focus on oncology and serious infectious diseases. For the past seven years, he has worked as a Pharmaceutical Advisor. Dr McCulloch is Chief Medical Officer of Gloucester Pharmaceuticals, Cambridge, US.


Dr Alexander von Nieciecki earned a PhD in pharmacology and is a registered Pharmacist for analytics and pharmaceutical technology. Since joining the pharmaceutical industry, he has been responsible for GMP production documentation and has spent over 10 years in charge of biopharmaceutics, pharmacokinetics and bioanalytics. Presently, he is CEO of BioProof, a contract service organisation which performs bioanalytics under GLP (LC-MS/MS, ELISA, bioassays), pharmacokinetic/ toxicokinetic evaluation and scientific writing.


Dr Wolfgang Meyer is a registered Pharmacist who joined the industry in 1987. Since then, he has worked in drug regulatory affairs within four companies (from small to big pharma, as well as biotech). Since 2001, he has been a Senior Director of European Drug Regulatory Affairs and Drug Safety at GPC Biotech AG in Munich.


Dr Benno Rattel is a Veterinarian who earned a PhD in pharmacology and board certifications in pharmacology, toxicology and animal welfare. For over 15 years, he has been responsible for the non clinical safety assessment of small molecules and biopharmaceutics. Presently, he is Senior Director of Drug Development at GPC Biotech AG.

spacer
Dr Konrad Burk
spacer
spacer
spacer
Dr William McCulloch
spacer
spacer
spacer
Dr Alexander von Nieciecki
spacer
spacer
spacer
Dr Wolfgang Meyer
spacer
spacer
spacer
Dr Benno Rattel
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TrialScope Taps Industry Veteran as CTO

JERSEY CITY, NJ, July 29, 2019 – TrialScope, the global leader in clinical trial transparency and compliance solutions, announces the appointment of Ruben Echandy as Chief Technology Officer.
More info >>

White Papers

Quality of Steel

Natoli Engineering Company, Inc.

Steel quality is the summation of how well a steel meets its specified chemistry, the cleanliness of the steel or degree to which it is free of impurities or inclusion, homogeneity of the microstructure, grain/carbide size and in some instances if it meets the mechanical requirements for that particular steel. In the design and manufacture of tablet compression tooling, nothing is more important than the quality of the materials being used. The best manufacturing principals maintaining the tightest tolerances will result in tool failure if the initial material quality is poor. Material quality is the fundamental building block upon which all successive value added steps are laid. The majority of all tablet compression tooling is produced from steel and steel quality is the subject of this article.
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement